Press Releases

11.12.2019
Iveric Bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled
11.05.2019
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11.04.2019
Iveric Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
10.29.2019
Iveric Bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer
10.28.2019
Iveric Bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
09.30.2019
CORRECTING and REPLACING Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
09.30.2019
Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
09.17.2019
Iveric Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
09.04.2019
Iveric Bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019
08.07.2019
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference